MMedXYNews
Ask AIHomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY News/Hematology-Oncology

Section

Hematology-Oncology

578 articles

Ask AI
All specialtiesHematology-OncologynewsClinical UpdatesCardiologyOncology

Latest updates

Clinical Updates

Red Blood Cell Exchange Transfusion for Severe Babesiosis: Evidence for Improved Survival and Clinical Outcomes

Recent multicenter data indicates that red blood cell exchange transfusion (ET) provides a nearly five-fold reduction in mortality and readmission for patients with severe babesiosis, challenging earlier smaller-scale observations.

Apr 3, 2026
Hematology-Oncology

Limited Success: Third-Line Therapy Yields Modest Responses in Steroid-Refractory aGvHD with GI Involvement

The CHRONOS study reveals that third-line therapy for steroid- and ruxolitinib-refractory aGvHD with GI involvement achieves only 36% overall response at Day 28, with concerning durability issues and high mortality rates in this heavily pre

Apr 3, 2026Sign in to read
Clinical Updates

Oncolytic Bovine Herpesvirus Type 1: A Novel Strategy for Immune Microenvironment Remodeling in Multiple Myeloma

This review explores the breakthrough potential of Bovine Herpesvirus Type 1 (BoHV-1) as an oncolytic agent in Multiple Myeloma, highlighting its ability to induce mitochondrial apoptosis, reprogram the immunosuppressive bone marrow niche,

Apr 3, 2026
Clinical Updates

Ribosome Collisions and the ZAK-Dependent Ribotoxic Stress Response: A Novel Therapeutic Vulnerability in Chronic Myeloid Leukemia

This review synthesizes evidence that BCR::ABL1 inhibitors induce ribosome collisions and ZAK-dependent apoptosis, highlighting the ribotoxic stress response as a critical pathway for TKI efficacy and a potential target to overcome resistan

Apr 3, 2026
Gastroenterology

Enterococcus faecalis Drives MHC-II Expression in Intestinal Epithelium: A Novel Mechanism Linking Gut Microbiome Dysbiosis to Lethal Graft-versus-Host Disease

Research reveals that Enterococcus faecalis colonization induces MHC-II expression in intestinal epithelial cells during graft-versus-host disease, with a lantibiotic-producing Blautia producta strain demonstrating potential to restore colo

Apr 3, 2026
Hematology-Oncology

Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib

A study of 48 patients with R/R AML treated with revumenib revealed that 52% experienced dynamic immunophenotypic changes. Achieving MRD-negative morphologic remission significantly improved overall survival, highlighting the necessity for

Mar 29, 2026Sign in to read
Clinical Updates

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation in Low-Incidence Settings: Risk Factors, Clinical Trajectories, and Screening Mandates

This review analyzes a decade-long nationwide study on TB after Allo-HSCT in France, revealing a 60/100,000 incidence rate, high extrapulmonary involvement, and the critical need for screening patients from high-incidence regions.

Mar 28, 2026Sign in to read
Cardiology

Beyond the Clot: Novel Proteomic Markers Redefine Venous Thromboembolism Risk

This large-scale proteomic analysis identifies 15 novel protein markers for venous thromboembolism, offering new insights into the roles of immunity and extracellular matrix regulation in VTE pathogenesis beyond traditional coagulation path

Mar 28, 2026
Hematology-Oncology

Targeting the Sugar Coat: Oncofetal Chondroitin Sulfate Emerges as a Precision ADC Target in AML

Researchers have identified oncofetal chondroitin sulfate (ofCS) as a novel target for antibody-drug conjugates in AML. Unlike traditional targets, ofCS is absent in healthy tissues, potentially reducing hematotoxicity and expanding treatme

Mar 27, 2026
Hematology-Oncology

Predictive Value of Sex Chromosome Loss in Sex-Mismatched Stem Cell Transplantation

This study identifies late-onset sex chromosome loss as a critical biomarker for predicting relapse and survival outcomes in patients following sex-mismatched stem cell transplantation.

Mar 25, 2026Sign in to read
Hematology-Oncology

Beyond Genetics: Targeting BMP and TAZ/TEAD Mechanotransduction to Reverse Chemoresistance in Acute Myeloid Leukemia

Recent research identifies BMPR1B and TAZ/TEAD as critical mechanotransduction drivers in relapsed AML. By targeting these pathways, clinicians may overcome the protective effects of bone marrow stiffening and intramedullary pressure, offer

Mar 24, 2026
Hematology-Oncology

Dose-Dense Stanford V Strategy Safely Spares Radiation in Most Pediatric Patients with Low-Risk Hodgkin Lymphoma

The PHC HOD08 study demonstrates that an 8-week dose-dense modified Stanford V regimen achieves high complete response rates, allowing over 75% of low-risk pediatric Hodgkin lymphoma patients to avoid radiotherapy while maintaining an excep

Mar 24, 2026
Hematology-Oncology

Ph+ Status and Hyperleukocytosis: Redefining CNS Relapse Risk in Adult ALL Post-Transplant

A large-scale retrospective study identifies Philadelphia chromosome positivity and high initial white blood cell counts as critical risk factors for central nervous system relapse in adult ALL patients following allogeneic HCT, suggesting

Mar 19, 2026
Clinical Updates

Improving Survival in Advanced Proliferative CMML: The Prognostic Impact of Stringent Cytoreduction and Novel Flow Cytometric Biomarkers

This review examines the impact of myeloproliferative control on survival in advanced CMML, highlighting the prognostic value of stringent cytoreduction and novel flow cytometric biomarkers such as classical monocytes and immature granulocy

Mar 19, 2026
Clinical Updates

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results

This review analyzes the Phase 3 Precision-T trial, demonstrating that Orca-T, a high-precision T-cell therapy, significantly improves chronic GVHD-free survival and reduces non-relapse mortality compared to standard-of-care prophylaxis in

Mar 19, 2026
Clinical Updates

Tuberculosis Post-Allogeneic Hematopoietic Stem Cell Transplantation: Insights from a Decade-Long Nationwide Study in a Low-Incidence Setting

This nationwide retrospective study in France highlights the rare but severe incidence of tuberculosis (TB) in Allo-HSCT recipients, identifying birth in high-prevalence countries as a primary risk factor and emphasizing the need for target

Mar 17, 2026
Hematology-Oncology

The NSUN2-FOSB Feedforward Loop: Unlocking m5C-Mediated Survival in Acute Myeloid Leukemia

Researchers identify a novel NSUN2-FOSB-BCL2L1 regulatory axis in AML that drives leukemia stem cell self-renewal through m5C RNA methylation. This pathway offers a potential therapeutic target that spares normal hematopoiesis, suggesting a

Mar 16, 2026
Hematology-Oncology

Beyond Blast Counts: How Menin Inhibition Redefines AML Immunophenotypes and Survival

This study explores how the menin inhibitor revumenib induces significant immunophenotypic shifts in AML patients. Results show that over 50% of patients undergo lineage changes, and achieving MRD negativity remains the strongest predictor

Mar 16, 2026Sign in to read
Clinical Updates

Targeting the Glycan Signature: Oncofetal Chondroitin Sulfate as a Selective Vulnerability in Acute Myeloid Leukemia

This review explores oncofetal chondroitin sulfate (ofCS) as a revolutionary AML target. Unlike traditional antigens, ofCS is absent in normal bone marrow, allowing antibody-drug conjugates to eliminate leukemia cells with minimal hematotox

Mar 16, 2026Sign in to read
Clinical Updates

Standardizing Outcomes Research: A Robust Extraction Pipeline for Hematopoietic Stem Cell Transplantation Registry Data

This review evaluates a novel open-source extraction pipeline designed to standardize and automate the processing of complex HSCT registry data, enhancing reproducibility and precision in clinical outcomes research.

Mar 13, 2026
Previous
18 / 25
1…1617181920…25
Next

Most read

  1. 01Hematology-Oncology

    Precision Immunotherapy in Acute Myeloid Leukemia: Advancing Beyond Traditional Targets

  2. 02Hematology-Oncology

    Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.